Biomind Labs Inc. Stock
Price
Target price
€0.44
€0.44
0.460%
0.002
0.460%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Biomind Labs Inc.
sharewise wants to provide you with the best news and tools for Biomind Labs Inc., so we directly link to the best financial data sources.
Financials
News
![Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease: https://mms.businesswire.com/media/20220217005440/en/1363327/5/Biomind_Logo_2022.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmo5Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2fe10e2011f4b07703d1ff35d359d71f545d7686/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Biomind_Logo_2022.jpg?locale=us)
Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease
Biomind Labs Inc. (“Biomind” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients